Abstract 368: Specific chromosomic alterations confer therapy resistance in a cohort of 49 patients with newly diagnosed acute myeloid leukemia treated with intensive chemotherapy
Cristina Papayannidis(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Giovanni Martinelli(University of Bologna), Simona Soverini(University of Bologna), Andrea Ghelli Luserna di Rorà(Fondazione Pisa), Chiara Sartor(University of Bologna), Maria Chiara Fontana(Istituto Oncologico Romagnolo), Maria Chiara Abbenante(University of Bologna), Emanuela Ottaviani(University of Bologna), Giovanni Marconi(University of Bologna), Silvia Lo Monaco(University of Bologna), Eugenia Franchini(University of Bologna), Sarah Parisi(University of Bologna), Elisa Zuffa(University of Bologna), Marco Manfrini(University of Padua), Giorgia Simonetti(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Viviana Guadagnuolo(University of Bologna), Antonella Padella(University of Bologna), Stefania Paolini(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Claudia Venturi(University of Bologna), Maria Teresa Bochicchio(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori)
Cited by 0
Related Papers
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
|Blood|2015|1.2k
Levofloxacin to Prevent Bacterial Infection in Patients with Cancer and Neutropenia
|New England Journal of Medicine|2005|644